Drug Safety Testing Center

Profile narrative

The Drug Safety Testing Center (DSC) operates under the alias DSC and is headquartered in China.
It provides drug safety testing services, as indicated by its name.
The centre’s core activity involves evaluating the safety of pharmaceutical products.
These services support regulatory compliance and public health objectives.

DSC’s specialisation lies in the safety assessment of drugs, positioning it within the pharmaceutical testing sector.
During a ransomware incident on 12 May 2025, the centre demonstrated a structured incident response by activating an internal task force.
It promptly disconnected and isolated the affected servers and reported the breach to law‑enforcement authorities.
In line with its regulatory obligations, DSC notified the Innovation, Technology and Industry Bureau, the Innovation and Technology Commission, the Digital Policy Office, and the Office of the Privacy Commissioner for Personal Data.
The centre also engaged its outsourced contractor and independent third‑party cybersecurity experts to conduct remediation, produce an investigation report, and cooperate with the police inquiry.

The incident highlights DSC’s capacity to coordinate with multiple governmental bodies and external cybersecurity professionals.
No explicit information regarding the organisation’s size, ownership, parent‑subsidiary relationships, or market reach is provided in the source material.
Consequently, details such as employee count, annual revenue, or subsidiary structure remain unspecified.
The profile is therefore limited to the confirmed facts about DSC’s function, location, and observed incident response behaviour.

Incidents

1 incident linked to this organisation.